Abstract：
The successful development of multikinase inhibitors over the last two decades has revolutionized the management of many malignant cancers. Agents such as the antiangiogenic kinase inhibitor sorafenib have certain advantages such as a broad spectrum of activity against cancer cells, vascular endothelial cells, and pericytes, and are the mainstay of treatment in diseases such as advanced renal or liver cancer. The more recent emergence of immunotherapy-using immune checkpoint blockade-in some of the same diseases has raised important questions about the treatment interaction with antiangiogenic drugs, seven such combinations have been approved for lung, liver, kidney, and endometrial cancers, and multiple combination therapies are being aggressively pursued in the clinic. Thus, revealing mechanisms of action of antiangiogenic kinase inhibitors in combination with immune checkpoint blockade is critical to improving the treatment outcome further. This Landmark commentary on sorafenib in cancer therapy highlights these important questions. See related article by Wilhelm et al., Cancer Res 2004;64:7099-109.
摘要：
在过去的二十年中，多激酶抑制剂的成功开发彻底改变了许多恶性肿瘤的管理。抗血管生成激酶抑制剂索拉非尼等药物具有某些优点，例如对癌细胞具有广谱的活性，血管内皮细胞,和周细胞,并且是晚期肾癌或肝癌等疾病的主要治疗手段。在一些相同的疾病中，使用免疫检查点阻断的免疫治疗的最新出现引发了关于与抗血管生成药物的治疗相互作用的重要问题。七个这样的组合已被批准用于肺部，肝脏,肾,子宫内膜癌，和多种联合疗法在临床上正在积极追求。因此，揭示抗血管生成激酶抑制剂联合免疫检查点阻断的作用机制对于进一步改善治疗结果至关重要.关于索拉非尼在癌症治疗中的具有里程碑意义的评论强调了这些重要问题。参见Wilhelm等人的相关文章。,癌症报告2004;64:7099-109。
